The Proactive write up is essentially a precis of the half year...

The Proactive write up is essentially a precis of the half year report.
It's already good story, certainly one capable of being interesting a wider audience, particularly once the potential application of Progenza can be used in other diseases than osteoarthritis becomes evident. RGS may find itself generating multiple listening and royalty streams in the coming years.

What will RGS do with Progenza in other markets? Will it seek other majors, or will Regeneus do a global deal with AGC? If the JV works out well, I am leaning towards the latter.


http://www.*.com.au/companies/news/...profit-funded-for-eighteen-months-173854.html